<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963922</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4272</org_study_id>
    <secondary_id>U1111-1177-4903</secondary_id>
    <secondary_id>2015-005619-33</secondary_id>
    <nct_id>NCT02963922</nct_id>
  </id_info>
  <brief_title>Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin</brief_title>
  <acronym>SCALEâ„¢ Insulin</acronym>
  <official_title>Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of this trial is to investigate effect and safety
      of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus
      treated with basal insulin.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">September 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>% change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects losing at least 5% of baseline body weight</measure>
    <time_frame>Week 56</time_frame>
    <description>% of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects losing more than 10% of baseline body weight</measure>
    <time_frame>Week 56</time_frame>
    <description>% of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (glycosylated haemoglobin)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting plasma glucose</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), physical function domain (5-items) score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 22-item modified version of an instrument designed to assess weight-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total daily basal insulin dose</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>% of pre-trial dose in U, and in U/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total daily insulin dose</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>% of pre-trial dose in U, and in U/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 7-point self-measured plasma glucose (SMPG) profile, mean daytime glucose value</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Mean glucose value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight related sign and symptom (WRSS) measure, total score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7% and weight loss above or equal to 5%</measure>
    <time_frame>Week 56</time_frame>
    <description>Proportion of subjects fulfilling both criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7%, weight loss above or equal to 5% and no documented symptomatic hypoglycaemia</measure>
    <time_frame>Week 56</time_frame>
    <description>Proportion of subjects fulfilling all three criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Above or equal to 3.8 T-score points increase from baseline in SF-36 PCS</measure>
    <time_frame>Week 56</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Above or equal to 4.6 T-score points increase from baseline in SF-36 MCS</measure>
    <time_frame>Week 56</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Week 0-56</time_frame>
    <description>Count and % of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>Week 0-56</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - total cholesterol</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - very low density lipoprotein cholesterol (VLDL)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - triglycerides</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - free fatty acids (FFA)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v2.0 acute, physical functioning score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: role-physical score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: bodily pain score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: general health score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: vitality score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: social functioning score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: role-emotional score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: mental health score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: physical component summary (PCS)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) v.2.0 acute: mental component summary (MCS)</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): pain/discomfort domain score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 22-item modified version of an instrument designed to assess weight-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): psychosocial domain score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 22-item modified version of an instrument designed to assess weight-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): total score</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <description>The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 22-item modified version of an instrument designed to assess weight-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Above or equal to 4.3 T-score points increase from baseline in SF-36 physical functioning score</measure>
    <time_frame>Week 56</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score</measure>
    <time_frame>56 weeks</time_frame>
    <description>The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 22-item modified version of an instrument designed to assess weight-related quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>liraglutide 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3.0 mg</intervention_name>
    <description>Injected subcutaneously (s.c., under the skin) once daily</description>
    <arm_group_label>liraglutide 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injected subcutaneously (s.c., under the skin) once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Diagnosed with type 2 diabetes mellitus

          -  Treatment with up to 2 OADs (oral anti-diabetic) (metformin, glitazone, SGLT-2
             inhibitor (sodium-glucose cotransporter-2 inhibitors) or sulphonylurea)

          -  Stable treatment with basal insulin according to its label (no requirement of minimum
             or maximum dose) for at least 90 days prior to screening, as judged by the
             investigator

          -  HbA1c (glycosylated haemoglobin) 6.0-10.0% (both inclusive)

          -  BMI (body mass index) equal to or above 27 kg/m^2

          -  Age at least 18 years at the time of signing informed consent

        Exclusion Criteria:

          -  Diagnosis of type 1 diabetes

          -  Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's
             questionnaire question 8 (see Section 8.2.3)

          -  Recurrent severe hypoglycaemic episodes within the last year as judged by the
             investigator

          -  Unable or unwilling to perform self-monitoring of plasma glucose according to the
             protocol and to keep a diabetes diary

          -  Treatment with any hypoglycaemic medications other than OADs and basal insulin within
             the past 90 days prior to screening

          -  Treatment with a DPP-IV (dipeptidyl peptidase-4) inhibitor within the past 90 days
             prior to screening

          -  Recent history of cardiovascular disease (myocardial infarction or stroke within the
             past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree
             or greater heart block

          -  Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine
             Neoplasia type 2 (MEN2)

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using an adequate contraceptive method (adequate
             contraceptive measure as required by local regulation or practice)

          -  For Germany: Only highly effective methods of birth control are accepted (i.e. one
             that results in less than 1% per year failure rate when used consistently and
             correctly such as implants, injectables, combined oral contraceptives, some
             intrauterine device), or sexual abstinence or vasectomised partner

          -  Use in past 90 days of medications known to induce significant weight loss (e.g.,
             prescription weight loss medications) or weight gain (e.g., chronic use of oral
             steroids, second generation antipsychotics)

          -  History of pancreatitis (acute or chronic)

          -  History of major depressive disorder within the past 2 years

          -  Any lifetime history of a suicide attempt

          -  Inadequately treated blood pressure defined as Grade 3 hypertension or higher
             (Systolic above or equal to 180 mmHg or diastolic above or equal to110 mmHg).

          -  History of malignancy (except for non-melanoma skin cancer) within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601-3834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6H 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6G 1M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <zip>66780</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Ingbert</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

